Efficacy, Adverse Events and Resistant Mechanism of Eribulin Combined With or Without Bevacizumab for Advanced HER2 Negative Breast Cancer Patients, an Open-label, Randomized, Multi-center PhaseⅡ Clinical Trial.
Latest Information Update: 09 Aug 2024
At a glance
- Drugs Bevacizumab (Primary) ; Eribulin (Primary)
- Indications HER2 negative breast cancer
- Focus Therapeutic Use
Most Recent Events
- 09 Aug 2024 New trial record